Maximal Ablative Irradiation Because of Encasement for Patients With Locally Advanced Pancreatic Cancer
JAMA Surgery · 01.09.2026 · 161 (9) · 891
DOI: 10.1001/jamasurg.2026.2988 ↗Kurz gefasst
Klinische Studie (Phase II) in der Zeitschrift JAMA Surgery, erschienen am 01.09.2026. Verfasst von Marsha Reyngold und 22 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, New York. Hauptthemen laut MEDLINE: Adenocarcinoma, Pancreatic Neoplasms. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 38 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Importance The best local therapy approach for patients with locally advanced pancreatic cancer (LAPC) remains undefined.
Objective
To evaluate hypofractionated ablative radiation therapy (A-RT) followed by evaluation for surgery in patients with LAPC whose cancer remained unresectable after induction chemotherapy. Design, Setting, and Participants This was a phase 2 single-arm nonrandomized clinical trial conducted at the Memorial Sloan Kettering Cancer Center, New York, New York, from June 2018 to April 2024. Participants with histologically confirmed pancreatic adenocarcinoma unresectable by multidisciplinary review after 3 or more months of modified fluorouracil, leucovorin, irinotecan, and oxaliplatin (mFOLFIRINOX) or gemcitabine plus nab-paclitaxel were eligible.
Intervention
Hypofractionated A-RT (67.5 Gy in 15 fractions or 75 Gy in 25 fractions) with capecitabine followed by evaluation for resection. Main Outcomes and Measures Coprimary end points included resectability and 2-year overall survival. Secondary end points included 90-day surgical adverse events (AEs) and 2-year locoregional and distant metastasis rates.
Results
Forty-eight participants underwent A-RT (25 [52.1%] male; median [range] age, 67 [50-80] years; median [range] tumor size 4.1 [2.4-8.3] cm; 47 (98%) with arterial and venous involvement; median [range] carbohydrate antigen 19-9, 88 [<1-1601] U/mL). Forty-five patients (94%) received mFOLFIRINOX. Seventeen participants (34%) underwent a laparoscopy, with resection performed in 13 (27%). Resections included 11 pancreaticoduodenectomies (84.6%) and 2 distal pancreatectomies (15.4%). At median follow-up of 3 years, 2-year overall survival from A-RT for the cohort was 38% (95% CI, 26%-54%) overall and 31% (95% CI, 19%-51%) and 54% (95% CI, 33%-89%) in participants with unresected and resected disease, respectively. Two-year rates of local progression were 11% (95% CI, 3.5%-25%) and 15% (95% CI, 2.2%-40%) in unresected and resected groups, respectively. Two-year rate of distant metastasis was 73% (95% CI, 57%-84%). There were no deaths within 90 days of surgery. Eleven surgical AEs (including 4 Clavien-Dindo grade III) occurred in 12 evaluable participants. Acute and late RT-related grade III or higher AEs occurred in 6 (12.5%) and 12 (26.1%) participants, respectively. The most common late AE was ascites in 7 (15.2%; 3 postsurgery).
Conclusions
For patients with LAPC with extensive vascular encasement after induction chemotherapy, hypofractionated A-RT prior to possible surgery was associated with promising overall survival for both ultimately resected and unresected groups. A-RT was not associated with an increase in postsurgical morbidity when surgery was performed and was an effective destination therapy when it was not. Further evaluation of this strategy to maximize outcomes regardless of resection is warranted. Trial Registration ClinicalTrials.gov Identifier: NCT03523312
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, New York.
- David M. Rubenstein Center for Pancreatic Cancer Research, New York, New York.
- Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York.
- Division of Solid Tumor Oncology, Memorial Sloan Kettering Cancer Center, New York, New York.
- Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, New York.
- Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, New York.
Zitieren
APA
Reyngold, M., Wei, A. C., O'Reilly, E. M., D'Angelica, M. I., Kingham, T. P., Soares, K. C., Varghese, A. M., White, C., Zinovoy, M., Romesser, P. B., Wu, A., Hajj, C., Cuaron, J. J., Khalil, D. N., Balogun, F., Park, W., Yu, K. H., Balachandran, V. P., Drebin, J. A., …, & Crane, C. H. (2026). Maximal Ablative Irradiation Because of Encasement for Patients With Locally Advanced Pancreatic Cancer. JAMA Surgery, 161(9), 891. https://doi.org/10.1001/jamasurg.2026.2988
Vancouver
Reyngold M, Wei AC, O'Reilly EM, D'Angelica MI, Kingham TP, Soares KC, et al. Maximal Ablative Irradiation Because of Encasement for Patients With Locally Advanced Pancreatic Cancer. JAMA Surgery. 2026;161(9):891. doi:10.1001/jamasurg.2026.2988
BibTeX
@article{Reyngold2026,
author = {Reyngold, Marsha and Wei, Alice C and O'Reilly, Eileen M and D'Angelica, Michael I and Kingham, T Peter and Soares, Kevin C and Varghese, Anna M and White, Charlie and Zinovoy, Melissa and Romesser, Paul B and Wu, Abraham and Hajj, Carla and Cuaron, John J and Khalil, Danny N and Balogun, Fiyinfolu and Park, Wungki and Yu, Kenneth H and Balachandran, Vinod P and Drebin, Jeffrey A and Lagratta, Maria and Zhang, Zhigang and Jarnagin, William R and Crane, Christopher H},
title = {Maximal Ablative Irradiation Because of Encasement for Patients With Locally Advanced Pancreatic Cancer},
journal = {JAMA Surgery},
year = {2026},
volume = {161},
number = {9},
pages = {891},
doi = {10.1001/jamasurg.2026.2988}
}
EUVIMED